Bought into the fold through the $5.8 billion acquisition of Stemcentrx in 2016, Rova-T – short for rovalpituzumab tesirine – had a great name and some tasty looking results from an early-to ...

One notable example occurred when AbbVie acquired Stemcentrx for $5.8 billion on the back of promising mid-stage trials data for Rova-T (rovalpituzumab tesirine), only for the compound to fail in ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...